Product image of SOTYKTU 6 mg/1 (Deucravacitinib) 6 mg/1 TABLET, FILM COATED supplied by GNH India

SOTYKTU 6 mg/1

Active Ingredient:
Deucravacitinib
Form:
TABLET, FILM COATED
Brand:
SOTYKTU
Origin:
USA

SOTYKTU 6 mg/1 (Deucravacitinib TABLET, FILM COATED) 6 mg/1

Deucravacitinib, the active ingredient in SOTYKTU, is a Tyrosine kinase 2 (TYK2) inhibitor presented as a 6 mg/1 tablet, film coated for oral use. It is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

GNH India supplies SOTYKTU as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Strength

6 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BLISTER PACK (0003-0895-91)

Manufacturer / TM Owner

E.R. Squibb & Sons, L.L.C.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

SOTYKTU is indicated for the treatment of immune-mediated diseases, specifically moderate to severe plaque psoriasis. It is designed to help manage symptoms in adults who require systemic therapy or phototherapy.

  • Plaque psoriasis: Reduces the severity and extent of skin lesions and improves overall skin condition.

How It Works

  • Deucravacitinib works by selectively inhibiting Tyrosine kinase 2 (TYK2), a key mediator in cytokine signaling pathways. By targeting TYK2, it modulates the activity of interleukins (IL-12, IL-23) and type I interferons, which are involved in inflammatory and immune responses. This modulation helps to reduce inflammation and immune overactivity associated with plaque psoriasis.

Side Effects

SOTYKTU may cause various side effects, ranging from common to serious. Patients should be monitored closely for any adverse reactions.

Common Side Effects

  • Upper respiratory tract infections, such as nasopharyngitis.
  • Headache.
  • Diarrhea.
  • Nausea.
  • Fatigue.
  • Acne.
  • Back pain.
  • Influenza.

Serious or Rare Side Effects

  • Serious infections, including opportunistic infections.
  • Malignancies, including skin cancers.
  • Major cardiovascular events.
  • Liver problems, including elevated liver enzymes.
  • Hypersensitivity reactions.

Precautions & Warnings

SOTYKTU should be used with caution in certain patient populations and conditions. Patients and healthcare providers should be aware of the following precautions.

  • Infections: Monitor for signs of infection before and during treatment.
  • Malignancies: Regular skin examinations are recommended to monitor for skin cancers.
  • Cardiovascular events: Assess cardiovascular risk factors before initiating treatment.
  • Liver function: Monitor liver enzymes regularly during treatment.
  • Hypersensitivity: Discontinue use if signs of hypersensitivity reactions occur.
  • Pregnancy and breastfeeding: Safety in pregnancy and breastfeeding has not been established; consult healthcare provider.
  • Store below 25°C: Keep in the original pack, protect from moisture.

Avoid Interactions

SOTYKTU may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Healthcare providers should be aware of the following interactions.

Major Interactions (Avoid)

  • Immunosuppressants: Increased risk of infections and malignancies.
  • Live vaccines: Avoid concurrent use due to potential for vaccine-related infections.
  • Strong CYP3A4 inducers: May decrease the effectiveness of SOTYKTU.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inducers: May require dose adjustment.
  • Moderate CYP3A4 inhibitors: May increase the risk of side effects.
  • Anticoagulants: Increased risk of bleeding.
  • Immunomodulators: May enhance immunosuppressive effects.

Frequently Asked Questions

SOTYKTU is used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It helps to reduce the severity and extent of skin lesions and improves overall skin condition.

Deucravacitinib works by selectively inhibiting Tyrosine kinase 2 (TYK2), a key mediator in cytokine signaling pathways. By targeting TYK2, it modulates the activity of interleukins (IL-12, IL-23) and type I interferons, which are involved in inflammatory and immune responses. This modulation helps to reduce inflammation and immune overactivity associated with plaque psoriasis.

The recommended dose of SOTYKTU is 6 mg, taken once daily orally. The prescriber will determine the appropriate dosage based on the patient's condition and response to treatment.

The safety of SOTYKTU during pregnancy and breastfeeding has not been established. Patients should consult their healthcare provider before using SOTYKTU if they are pregnant, planning to become pregnant, or breastfeeding.

To order SOTYKTU from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

SOTYKTU is a selective TYK2 inhibitor, which differentiates it from other treatments like apremilast and placebo. Clinical studies have shown that SOTYKTU is more effective than apremilast and placebo in achieving significant improvements in plaque psoriasis symptoms.

SOTYKTU should be stored below 25°C, kept in the original pack, and protected from moisture. Proper storage ensures the stability and efficacy of the medication.

SOTYKTU is administered orally, with a recommended dose of 6 mg once daily. Patients should follow the prescribed dosage and administration instructions provided by their healthcare provider.

The most serious risks associated with SOTYKTU include serious infections, malignancies, major cardiovascular events, liver problems, and hypersensitivity reactions. Patients should be monitored closely for these potential risks.

SOTYKTU should not be used by patients with known hypersensitivity to Deucravacitinib or any of its components. Patients with active serious infections or a history of serious infections should also avoid using SOTYKTU unless directed by a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Deucravacitinib

Zepbound 2.5 mg/.5mL

Zepbound 2.5 mg/.5mL

2.5 mg/.5mL INJECTION, SOLUTION
Zepbound 2.5 mg/.5mL

Zepbound 2.5 mg/.5mL

2.5 mg/.5mL INJECTION, SOLUTION
Zepbound 2.5 mg/.5mL

Zepbound 2.5 mg/.5mL

2.5 mg/.5mL INJECTION, SOLUTION
Humulin R 100 [iU]/mL

Humulin R 100 [iU]/mL

100 [iU]/mL INJECTION, SOLUTION

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT